{"id":"NCT02954575","sponsor":"Octapharma","briefTitle":"Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A","officialTitle":"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2018-03-29","completion":"2018-03-29","firstPosted":"2016-11-03","resultsPosted":"2019-12-03","lastUpdate":"2021-01-19"},"enrollment":57,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"DRUG","name":"Wilate","otherNames":["von Willebrand factor / Factor VIII (plasma derived)"]}],"arms":[{"label":"All patients","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with Wilate for 6 months and at least 50 EDs, thus supplementing the existing database to obtain approval of Wilate for the indication hemophilia A in the USA.","primaryOutcome":{"measure":"Total Annualized Bleeding Rate (TABR)","timeFrame":"6 months","effectByArm":[{"arm":"Wilate","deltaMin":2.1,"sd":3.44}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["Bulgaria","Hungary","Poland","Romania","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Thrombocytosis","Seasonal allergy","Arthralgia","Erysipelas","Nasopharyngitis"]}}